Background
MedImmune was a biotechnology company that licensed patents from Genentech covering the manufacture of Synagis, MedImmune’s blockbuster drug for treating respiratory syncytial virus in infants. MedImmune paid royalties under the license but believed that the licensed patents were invalid or that Synagis did not infringe them. Rather than stop paying royalties — which would have exposed it to an infringement lawsuit — MedImmune continued paying under the license while simultaneously bringing a declaratory judgment action seeking a court ruling that the patents were invalid and not infringed.
The district court dismissed MedImmune’s declaratory judgment claims for lack of subject matter jurisdiction. Under the prevailing test for declaratory judgment jurisdiction in patent cases, a challenger had to demonstrate a “reasonable apprehension of suit” — and a licensee currently in good standing under a license and paying royalties could not demonstrate such apprehension. The district court concluded that MedImmune, as a current licensee in compliance with its obligations, had no reasonable apprehension of an infringement suit and therefore lacked standing to bring a declaratory judgment action.
MedImmune appealed to the Federal Circuit, which affirmed the dismissal. The case then went to the Supreme Court, where the landscape changed entirely.
The Court’s Holding
The Federal Circuit affirmed the district court, holding that a licensee in good standing — one that is currently paying royalties and complying with the terms of its license — cannot bring a declaratory judgment action challenging the licensed patent’s validity. The court relied on the principle that such a licensee faces no reasonable apprehension of patent infringement suit because the license itself provides a complete defense. Without the threat or reasonable apprehension of suit, the Federal Circuit held that no actual controversy existed under the Declaratory Judgment Act, and federal courts therefore lacked jurisdiction to hear the challenge.
The practical effect of this rule was significant: a licensee who wanted to challenge the validity of a licensed patent was essentially required to stop paying royalties and breach the license, thereby exposing itself to an infringement lawsuit — only then could it raise validity as a defense. This “shoot first, ask questions later” requirement was widely criticized as creating a disproportionate barrier to patent validity challenges, particularly for smaller companies that could not afford to abandon the protection of a license agreement.
The Supreme Court unanimously reversed in January 2007, holding that a licensee need not terminate or breach its license to challenge patent validity via declaratory judgment. The Supreme Court applied the general standard for declaratory judgment jurisdiction — whether there is a “case or controversy” of sufficient concreteness and adversity — rather than the specific “reasonable apprehension of suit” test that the Federal Circuit had used.
Key Takeaways
- The Federal Circuit’s “reasonable apprehension of suit” test for declaratory judgment jurisdiction in patent cases was ultimately rejected by the Supreme Court as too narrow.
- Under the Federal Circuit’s rule (before reversal), a licensee in good standing could not bring a declaratory judgment action challenging the licensed patent without first breaching the license.
- The Supreme Court reversed, holding that the Declaratory Judgment Act’s “case or controversy” requirement is satisfied when the parties have adverse legal interests of sufficient immediacy and reality — regardless of whether the licensee continues to pay royalties.
- After MedImmune (SCOTUS), licensees can challenge the validity of patents they are licensing without first terminating the license or risking an infringement suit.
- This case fundamentally changed the balance of power in patent licensing negotiations and patent validity challenges.
Why It Matters
The Federal Circuit’s MedImmune decision — subsequently reversed by the Supreme Court — illustrates a recurring pattern of that era: the Federal Circuit applying rules that strongly favored patent holders, followed by Supreme Court correction. By requiring licensees to breach their agreements before challenging patent validity, the Federal Circuit’s rule had effectively insulated questionable patents from challenge by the very parties most likely to know whether they were valid and most directly harmed if they were not.
The Supreme Court’s reversal in MedImmune v. Genentech (2007) transformed patent licensing by empowering licensees to challenge the patents they license without jeopardizing their business operations. The ruling had broad practical significance for the pharmaceutical, biotechnology, and technology industries, where licensing of potentially questionable patents is common. It also continued the Supreme Court’s pattern in the mid-2000s of correcting what it viewed as overly pro-patentee Federal Circuit doctrines, a pattern that also produced the eBay injunction decision and the KSR obviousness ruling.